Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Theralase versus Delta
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(131)
•••
Comment by gojotv!on Aug 29, 2021 3:49pm
259 Views
Post# 33779796

RE:RE:Theralase versus Delta

RE:RE:Theralase versus DeltaWow. Your post is almost entirely inaccurate, skys1. First, TLT has 20 patients who have received the full dosage and 90+ days, and who are eligible for consideration for
not Fast Track Designation,
but Breakthrough Status.
There is also a pssibility that we could get Accelerated Approval if data is good enough...
IMO, Shirazi was replaced because TLT needs a better communicator at the helm. Media attention is fleeting and unforgiving. It must be seized by someone who can get the message out in the right bites.

skys1 wrote: I'd be surprised if there have been 8 new enrolled patients. I suspect it is closer to 2 or 3. 8 would get TLT to the 20-25 needed to apply for FTD. Don't forget Shawn was forced out for some reason. I suspect it was the trial was progressing too slowly.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities